NEU neuren pharmaceuticals limited

Ann: 2023 Annual Report to shareholders, page-129

  1. 1,477 Posts.
    lightbulb Created with Sketch. 373
    Yep great post @hottod (as usual).

    I think the key difference between OPT and NEU is that Neuren are already starting with a decent warchest and a steady stream of income.

    Also the way I read the "tea leaves" currently is that if - and thats IF - Neuren choose to go to P3 alone it seems they are only doing this for PMS only at this stage.

    Ttherefore - assuming the above - I feel the dilution/investment that Neuren would need to see this alone would be another circa $300m-ish....guessing....maybe....which I would expect (IMO - guesstimate !!) they could raise under their 15% placement rule assuming they have good P2 announcements and SP appreciation.

    Summarising - if ive guestimated the above correctly - I feel we will know very soon post the P2 results whether Neuren will partner up for P3 PMS, go it alone or nothing.

    If its nothing, IMO this also indicates to me they are looking for either a T/O or being bought...as it wouldnt make commercial sense to take advantage of the news.

    Thats my musings for the day.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.54
Change
0.100(0.80%)
Mkt cap ! $1.559B
Open High Low Value Volume
$12.44 $12.73 $12.13 $11.07M 885.6K

Buyers (Bids)

No. Vol. Price($)
1 1215 $12.52
 

Sellers (Offers)

Price($) Vol. No.
$12.54 804 1
View Market Depth
Last trade - 16.10pm 20/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.